Additional file 1: Table S1. of In vitro antibacterial and antibiotic-potentiation activities of the methanol extracts from Beilschmiedia acuta, Clausena anisata, Newbouldia laevis and Polyscias fulva against multidrug-resistant Gram-negative bacteria

MICs up to 1024 μg/mL of the crude extracts and ciprofloxacin on the panel of tested bacteria. Table S2. MBCs up to 1024 μg/mL of the crude extracts and ciprofloxacin on the panel of tested bacteria. (DOCX 29 kb

Additional file 1: of In vitro antibacterial and antibiotic modifying activity of crude extract, fractions and 3′,4′,7-trihydroxyflavone from Myristica fragrans Houtt against MDR Gram-negative enteric bacteria

NMR data of 3′,4′,7-trihydroxyflavone. 1H NMR, 13C NMR spectra and chemical shifts of isolated compound. (DOCX 453 kb

A kaempferol triglycoside from <i>Tephrosia preussii</i> Taub. (Fabaceae)

<p>A phytochemical investigation of the MeOH extract of twigs and leaves of <i>Tephrosia preussi</i> was carried out to give a new kaempferol triglycoside, named tephrokaempferoside (<b>1</b>), together with five known compounds: tephrosin (<b>2</b>), betulinic acid (<b>3</b>), lupeol (<b>4</b>), <i>β</i>-sitosterol (<b>5</b>) and 3-<i>O</i>-<i>β</i>-d-glucopyranoside of <i>β</i>-sitosterol (<b>6</b>). The structure of the new compound was characterised by analyses of NMR (1D and 2D) and MS data, and chemical conversion. Tephrokaempferoside (<b>1</b>) had weak antibacterial activity against <i>Klebsiella pneumoniae</i> with an MIC value of 150 μg/mL.</p

2D structures of the isolated compounds.

<p>DES1-Quercitrin, DES2-Afzelin, DES3-Quercetin, DES4-methyl 3,4,5-trihydroxybenzoate ; DES5-Sitosterol 3-O-β-D-glucopyranoside sterol .</p

Variation of IC₅₀ against Dd2 with exposure time.

<p>IC₅₀ after 24 hours in blue; IC50 after 48 hours in red. The IC50 values presented were obtained from two distinct experiments run in duplicate each.</p

Chemical structures of the studied compounds.

<p><b>1:</b> xanthone V₁, <b>2:</b> 2-acetylfuro-1,4-naphthoquinone; <b>3:</b> physcion; <b>4:</b> bisvismiaquinone; <b>5:</b> vismiaquinone; <b>6:</b> 1,8-dihydroxy-3-geranyloxy-6-methylanthraquinone.</p

Enzymatic activity of caspase 3/7 after 6 h treatment of CCRF-CEM cells with compounds 1.

<p>The activity of caspase 3/7 is expressed as percentage % relative to untreated cells. Compound <b>2</b> did not show any induction of caspase 3/7 activity (data not shown). Values are mean ± SD of three duplicated experiments.</p

Growth percentage (%) of compounds and doxorubicin tested at 20 µg/ml on CCRF-CEM, CEM/ADR5000 and MiaPaCa-2 cell lines.

<p><b>1:</b> xanthone V₁, <b>2:</b> 2-acetylfuro-1,4-naphthoquinone; <b>3:</b> physcion; <b>4:</b> bisvismiaquinone; <b>5:</b> vismiaquinone; <b>6:</b> 1,8-dihydroxy-3-geranyloxy-6-methylanthraquinone. Data with different superscript letters are significantly different (P<0.05).</p

Cytotoxicity of compounds <b>1</b>, <b>2</b> and doxorubicin on different cancer cell lines.

<p>*EC₅₀: effective dose showing 50% inhibition of growth proliferation.</p

Cell cycle distribution with Leukemia CCRF-CEM treated with compounds 2.

<p><b>A1</b>: control after 24 h; <b>A2</b>: control after 48 h; <b>A3</b>: control after 72 h; <b>B1</b>: treated with 2×IC₅₀ after 24 h; <b>B2</b>: treated with 2×IC₅₀ after 48 h; <b>B3</b>: treated with 2×IC₅₀ after 72 h; <b>C1</b>: treated with 2×IC₅₀ after 24 h; <b>C2</b>: treated with 2×IC₅₀ after 48 h; <b>C3</b>: treated with 2×IC₅₀ after 72 h; <b>D1</b>: treated with 2×IC₅₀ after 24 h; <b>D2</b>: treated with 2×IC₅₀ after 48 h; <b>D3</b>: treated with 2×IC₅₀ after 72 h.</p